Menu
 

Neuroscience Nursing Annual Conference

Saturday, March 12 - Tuesday, March 15, 2022

Rising Together

Virtual Industry Posters (Non-CE)

Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients with Schizophrenia/Schizoaffective Disorder Treated with a VMAT2 Inhibitors

Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with antipsychotic exposure. This real-world study of VMAT2-treated patients was performed to assess the association between patient awareness of TD symptoms and clinician-assessed symptom severity.

View the poster

Sponsored by

Neurocrine Logo

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia (TD)

AIMS total score (sum of items 1-7) is usually the primary efficacy measure in TD trials. However, AIMS item 8, which measures global severity of abnormal movements, might be an appropriate assessment in clinical practice. We analyze AIMS item 8 using data from a long-term study of valbenazine.

View the poster

Sponsored by

Neurocrine Logo

Please forward all questions regarding our posters to medinfo@neurocrine.com.


What's Next for Tardive Dyskinesia? Expert Insights from a Cross-Disciplinary Virtual Treatment Panel

Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged antipsychotic use. Despite the availability of approved TD medications, diagnosis and treatment can be challenging. We present findings from panel discussions with healthcare professionals who participated in virtual interviews regarding the diagnosis and treatment of TD.

View the poster

Sponsored by

Neurocrine Logo

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Characteristics of Patients Who Self-Administered Diazepam Nasal Spray for Seizure Clusters: Interim Results From a Phase 3, Open-Label, Repeat-Dose Safety Study

Self-administration of diazepam nasal spray (VALTOCO®) for seizure clusters represents a possible benefit over routes requiring a care partner. Nearly half of surveyed patients self-administering in this phase 3 study reported dosing primarily at the first signs a cluster was coming. This suggests patients took steps to self-control their treatment.

View the poster

Sponsored by

neurelis logo

 


Effect of Nabiximols Cannabinoid Oromucosal Spray on Spasticity and Muscle Strength in Persons With Multiple Sclerosis Across 3 Randomized Controlled Trials

View the poster

Sponsored by

Greenwich Biosciences

Please forward all questions regarding our posters to medinfo@greenwichbiosciences.com.


Safety and Efficacy of Nabiximols in People With Multiple Sclerosis Associated Spasticity: Post Hoc Analyses of a Controlled Enrichment Design Study

View the poster

Sponsored by

Greenwich Biosciences

Please forward all questions regarding our posters to medinfo@greenwichbiosciences.com.